Hologic, Inc. (HOLX) EV/EBITDA Ratio: 17.28x
Is Hologic, Inc.’s EV/EBITDA ratio high or low?
Hologic, Inc.'s EV/EBITDA ratio of 17.28x is 39% above its 5-year average of 12.41x, near the high end of its 5-year range (6.17x–19.44x).
As of Thursday, June 11, 2026. 15.14% above its 12-month average of 15.01x.
HOLX EV/EBITDA Ratio Chart
HOLX Average EV/EBITDA Ratio Chart
HOLX Current vs Average EV/EBITDA Ratio Chart
HOLX EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
17.28x
EV/EBITDA RATIO AVG TTM
15.01x
EV/EBITDA RATIO AVG 3Y
15.35x
EV/EBITDA RATIO AVG 5Y
12.41x
EV/EBITDA RATIO AVG 10Y
19.98x
EV/EBITDA RATIO AVG 15Y
18.87x
EV/EBITDA RATIO AVG 20Y
19.58x
CURRENT VS TTM AVG
+15.14%
CURRENT VS 3Y AVG
+12.54%
CURRENT VS 5Y AVG
+39.24%
CURRENT VS 10Y AVG
-13.49%
CURRENT VS 15Y AVG
-8.42%
CURRENT VS 20Y AVG
-11.76%
HOLX Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hologic, Inc. (HOLX) | $16.97B | 17.28x | 15.01x | 15.35x | 12.41x |
| Moderna, Inc. (MRNA) | $18.71B | N/A | 12.39x | 25.27x | 25.27x |
| Align Technology, Inc. (ALGN) | $12.27B | 13.98x | 13.90x | 20.40x | 25.86x |
| BioNTech SE (BNTX) | $22.39B | N/A | 51.40x | 19.63x | 20.05x |
| Mettler-Toledo International Inc. (MTD) | $22.82B | 20.23x | 23.55x | 23.87x | 26.49x |
| Waters Corporation (WAT) | $23.21B | 37.79x | 21.59x | 21.24x | 21.45x |
| Baxter International Inc. (BAX) | $10.49B | 24.37x | 20.31x | 19.09x | 19.10x |
| Charles River Laboratories International, Inc. (CRL) | $8.94B | 14.86x | 19.01x | 15.54x | 17.40x |
| Bio-Rad Laboratories, Inc. (BIO) | $7.92B | 254.89x | 59.27x | 93.59x | 48.31x |
| Veeva Systems Inc. (VEEV) | $26.31B | 19.71x | 33.42x | 44.03x | 54.13x |
EV/EBITDA vs. its own history
At 17.3, EV/EBITDA is in its normal range, sitting higher than 64% of its 20-year history.
20-year low
6.2
median
15.2
20-year high
80.3
Hologic, Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Hologic, Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Hologic, Inc. (HOLX)?
- The EV/EBITDA ratio for HOLX stock is 17.28x.
- Is Hologic, Inc.'s EV/EBITDA ratio high or low?
- Hologic, Inc.'s EV/EBITDA ratio of 17.28x is 39% above its 5-year average of 12.41x, near the high end of its 5-year range (6.17x–19.44x).
- What is the TTM average EV/EBITDA ratio for Hologic, Inc. (HOLX)?
- The TTM average EV/EBITDA ratio for HOLX stock is 15.01x.
- What is the 3Y average EV/EBITDA ratio for Hologic, Inc. (HOLX)?
- The 3Y average EV/EBITDA ratio for HOLX stock is 15.35x.
- What is the 5Y average EV/EBITDA ratio for Hologic, Inc. (HOLX)?
- The 5Y average EV/EBITDA ratio for HOLX stock is 12.41x.
- What is the 10Y average EV/EBITDA ratio for Hologic, Inc. (HOLX)?
- The 10Y average EV/EBITDA ratio for HOLX stock is 19.98x.
- What is the 15Y average EV/EBITDA ratio for Hologic, Inc. (HOLX)?
- The 15Y average EV/EBITDA ratio for HOLX stock is 18.87x.
- What is the 20Y average EV/EBITDA ratio for Hologic, Inc. (HOLX)?
- The 20Y average EV/EBITDA ratio for HOLX stock is 19.58x.
Hologic, Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-04-07 | 17.28x |
| 2026-04-06 | 17.28x |
| 2026-04-02 | 17.20x |
| 2026-04-01 | 17.19x |
| 2026-03-31 | 17.19x |
| 2026-03-30 | 17.18x |
| 2026-03-27 | 17.21x |
| 2026-03-26 | 17.21x |
| 2026-03-25 | 17.17x |
| 2026-03-24 | 17.18x |
| 2026-03-23 | 17.20x |
| 2026-03-20 | 17.15x |
| 2026-03-19 | 17.13x |
| 2026-03-18 | 17.09x |
| 2026-03-17 | 17.07x |
| 2026-03-16 | 17.09x |
| 2026-03-13 | 17.08x |
| 2026-03-12 | 17.10x |
| 2026-03-11 | 17.15x |
| 2026-03-10 | 17.18x |
| 2026-03-09 | 17.19x |
| 2026-03-06 | 17.22x |
| 2026-03-05 | 17.22x |
| 2026-03-04 | 17.21x |
| 2026-03-03 | 17.16x |
| 2026-03-02 | 17.16x |
| 2026-02-27 | 17.14x |
| 2026-02-26 | 17.11x |
| 2026-02-25 | 17.13x |
| 2026-02-24 | 17.13x |
| 2026-02-23 | 17.15x |
| 2026-02-20 | 17.15x |
| 2026-02-19 | 17.09x |
| 2026-02-18 | 17.10x |
| 2026-02-17 | 17.09x |
| 2026-02-13 | 17.07x |
| 2026-02-12 | 17.04x |
| 2026-02-11 | 17.08x |
| 2026-02-10 | 17.09x |
| 2026-02-09 | 17.06x |
| 2026-02-06 | 17.01x |
| 2026-02-05 | 16.99x |
| 2026-02-04 | 16.96x |
| 2026-02-03 | 16.97x |
| 2026-02-02 | 17.00x |
| 2026-01-30 | 17.04x |
| 2026-01-29 | 17.05x |
| 2026-01-28 | 16.28x |
| 2026-01-27 | 16.30x |
| 2026-01-26 | 16.30x |
| 2026-01-23 | 16.27x |
| 2026-01-22 | 16.28x |
| 2026-01-21 | 16.29x |
| 2026-01-20 | 16.28x |
| 2026-01-16 | 16.25x |
| 2026-01-15 | 16.26x |
| 2026-01-14 | 16.29x |
| 2026-01-13 | 16.23x |
| 2026-01-12 | 16.23x |
| 2026-01-09 | 16.23x |
| 2026-01-08 | 16.23x |
| 2026-01-07 | 16.25x |
| 2026-01-06 | 16.24x |
| 2026-01-05 | 16.21x |
| 2026-01-02 | 16.17x |
| 2025-12-31 | 16.15x |
| 2025-12-30 | 16.16x |
| 2025-12-29 | 16.16x |
| 2025-12-26 | 16.15x |
| 2025-12-24 | 16.15x |
| 2025-12-23 | 16.23x |
| 2025-12-22 | 16.24x |
| 2025-12-19 | 16.25x |
| 2025-12-18 | 16.25x |
| 2025-12-17 | 16.24x |
| 2025-12-16 | 16.26x |
| 2025-12-15 | 16.30x |
| 2025-12-12 | 16.26x |
| 2025-12-11 | 16.22x |
| 2025-12-10 | 16.22x |
| 2025-12-09 | 16.24x |
| 2025-12-08 | 16.23x |
| 2025-12-05 | 16.25x |
| 2025-12-04 | 16.23x |
| 2025-12-03 | 16.26x |
| 2025-12-02 | 16.22x |
| 2025-12-01 | 16.23x |
| 2025-11-28 | 16.25x |
| 2025-11-26 | 16.22x |
| 2025-11-25 | 16.23x |
| 2025-11-24 | 16.21x |
| 2025-11-21 | 16.13x |
| 2025-11-20 | 16.08x |
| 2025-11-19 | 16.09x |
| 2025-11-18 | 16.07x |
| 2025-11-17 | 16.04x |
| 2025-11-14 | 16.05x |
| 2025-11-13 | 16.07x |
| 2025-11-12 | 16.13x |
| 2025-11-11 | 16.14x |
| 2025-11-10 | 16.08x |
| 2025-11-07 | 16.04x |
| 2025-11-06 | 16.05x |
| 2025-11-05 | 16.06x |
| 2025-11-04 | 16.04x |
| 2025-11-03 | 16.03x |
| 2025-10-31 | 16.00x |
| 2025-10-30 | 16.00x |
| 2025-10-29 | 16.01x |
| 2025-10-28 | 16.02x |
| 2025-10-27 | 16.01x |
| 2025-10-24 | 16.01x |
| 2025-10-23 | 15.99x |
| 2025-10-22 | 16.00x |
| 2025-10-21 | 16.01x |
| 2025-10-20 | 15.58x |
| 2025-10-17 | 15.16x |
| 2025-10-16 | 14.88x |
| 2025-10-15 | 14.57x |
| 2025-10-14 | 14.35x |
| 2025-10-13 | 14.26x |
| 2025-10-10 | 14.73x |
| 2025-10-09 | 14.90x |
| 2025-10-08 | 14.85x |
| 2025-10-07 | 14.72x |
| 2025-10-06 | 14.64x |
| 2025-10-03 | 14.82x |
| 2025-10-02 | 14.76x |
| 2025-10-01 | 14.58x |
| 2025-09-30 | 14.67x |
| 2025-09-29 | 14.60x |
| 2025-09-26 | 14.61x |
| 2025-09-25 | 14.32x |
| 2025-09-24 | 14.44x |
| 2025-09-23 | 14.70x |
| 2025-09-22 | 14.63x |
| 2025-09-19 | 14.43x |
| 2025-09-18 | 14.83x |
| 2025-09-17 | 14.82x |
| 2025-09-16 | 13.81x |
| 2025-09-15 | 13.91x |
| 2025-09-12 | 14.04x |
| 2025-09-11 | 14.44x |
| 2025-09-10 | 14.26x |
| 2025-09-09 | 14.51x |
| 2025-09-08 | 14.47x |
| 2025-09-05 | 14.52x |
| 2025-09-04 | 14.44x |
| 2025-09-03 | 14.41x |
| 2025-09-02 | 14.49x |
| 2025-08-29 | 14.59x |
| 2025-08-28 | 14.49x |
| 2025-08-27 | 14.51x |
| 2025-08-26 | 14.49x |
| 2025-08-25 | 14.60x |
| 2025-08-22 | 14.83x |
| 2025-08-21 | 14.60x |
| 2025-08-20 | 14.93x |
| 2025-08-19 | 14.74x |
| 2025-08-18 | 14.62x |
| 2025-08-15 | 14.74x |
| 2025-08-14 | 14.79x |
| 2025-08-13 | 14.98x |
| 2025-08-12 | 14.77x |
| 2025-08-11 | 14.77x |
| 2025-08-08 | 14.79x |
| 2025-08-07 | 14.76x |
| 2025-08-06 | 14.55x |
| 2025-08-05 | 14.74x |
| 2025-08-04 | 14.76x |
| 2025-08-01 | 14.60x |
| 2025-07-31 | 14.53x |
| 2025-07-30 | 14.32x |
| 2025-07-29 | 14.53x |
| 2025-07-28 | 14.46x |
| 2025-07-25 | 14.63x |
| 2025-07-24 | 14.54x |
| 2025-07-23 | 14.51x |
| 2025-07-22 | 14.39x |
| 2025-07-21 | 14.05x |
| 2025-07-18 | 14.11x |
| 2025-07-17 | 14.12x |
| 2025-07-16 | 14.09x |
| 2025-07-15 | 13.96x |
| 2025-07-14 | 14.24x |
| 2025-07-11 | 14.47x |
| 2025-07-10 | 14.70x |
| 2025-07-09 | 14.49x |
| 2025-07-08 | 14.30x |
| 2025-07-07 | 14.19x |
| 2025-07-03 | 14.27x |
| 2025-07-02 | 14.38x |
| 2025-07-01 | 14.39x |
| 2025-06-30 | 14.35x |
| 2025-06-27 | 14.32x |
| 2025-06-26 | 14.34x |
| 2025-06-25 | 14.17x |
| 2025-06-24 | 14.28x |
| 2025-06-23 | 14.20x |
| 2025-06-20 | 14.21x |
| 2025-06-18 | 14.11x |
| 2025-06-17 | 14.14x |
| 2025-06-16 | 14.36x |
| 2025-06-13 | 14.27x |
| 2025-06-12 | 14.36x |
| 2025-06-11 | 14.23x |
| 2025-06-10 | 14.35x |
| 2025-06-09 | 14.23x |
| 2025-06-06 | 14.18x |
| 2025-06-05 | 13.92x |
| 2025-06-04 | 13.82x |
| 2025-06-03 | 13.92x |
| 2025-06-02 | 13.71x |
| 2025-05-30 | 13.74x |
| 2025-05-29 | 13.89x |
| 2025-05-28 | 14.05x |
| 2025-05-27 | 13.74x |
| 2025-05-23 | 12.12x |
| 2025-05-22 | 12.16x |
| 2025-05-21 | 12.23x |
| 2025-05-20 | 12.57x |
| 2025-05-19 | 12.56x |
| 2025-05-16 | 12.64x |
| 2025-05-15 | 12.42x |
| 2025-05-14 | 12.34x |
| 2025-05-13 | 12.70x |
| 2025-05-12 | 13.05x |
| 2025-05-09 | 12.63x |
| 2025-05-08 | 12.51x |
| 2025-05-07 | 12.36x |
| 2025-05-06 | 11.88x |
| 2025-05-05 | 11.80x |
| 2025-05-02 | 12.10x |
| 2025-05-01 | 10.47x |
| 2025-04-30 | 10.63x |
| 2025-04-29 | 10.65x |
| 2025-04-28 | 10.61x |
| 2025-04-25 | 10.60x |
| 2025-04-24 | 10.64x |
| 2025-04-23 | 10.62x |
| 2025-04-22 | 10.63x |
| 2025-04-21 | 10.41x |
| 2025-04-17 | 10.52x |
| 2025-04-16 | 10.33x |
| 2025-04-15 | 10.57x |
| 2025-04-14 | 10.74x |
| 2025-04-11 | 10.57x |
| 2025-04-10 | 10.45x |
| 2025-04-09 | 10.82x |
| 2025-04-08 | 10.67x |
| 2025-04-07 | 11.16x |
| 2025-04-04 | 11.09x |
| 2025-04-03 | 11.23x |
| 2025-04-02 | 11.04x |
| 2025-04-01 | 11.18x |
| 2025-03-31 | 11.24x |
| 2025-03-28 | 11.17x |
| 2025-03-27 | 11.34x |
| 2025-03-26 | 11.19x |
| 2025-03-25 | 11.08x |
Showing the most recent 260 of 4,531 data points. The chart above shows the full history.
Related Metrics
About Hologic, Inc.
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Paul Malenchini